Pharmaceutical / Drug Definition :
Inhibits alpha-glucosidases, enzymes that convert oligosaccharides and disaccharides to glucose. This inhibition lowers blood glucose level, especially in postprandial hyperglycemia
In the United States, Repaglinide is regulated by the U.S. Food and Drug Administration (FDA). FDA has specific requirements regarding the registration and listing of Repaglinide.
Repaglinide (Repaglinide Entry Refusal)
General U.S. Food and Drug Administration Guidelines for:
- Manufacturers Repaglinide (Repaglinide Suppliers)
- Processors Repaglinide
- Repackers Repaglinide
- Relabelers Repaglinide
- Exporters Repaglinide
- Importers Repaglinide
For more information about Repaglinide, simply click below:
U.S. FDA Regulations:
U.S. FDA Regulation: 21 C.F.R. Part 207
Registrar Corp assists businesses with U.S. FDA compliance. Certificates of Registration issued by Registrar Corp provide confirmation to industry that you are fulfilling U.S. FDA registration requirements. U.S. FDA does not issue or recognize Certificates of Registration. Registrar Corp is not affiliated with the U.S. Food and Drug Administration.